BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1160 related articles for article (PubMed ID: 12518369)

  • 1. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
    Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
    Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
    Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
    Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
    Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
    BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
    Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
    Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
    van der Horst CM; Saag MS; Cloud GA; Hamill RJ; Graybill JR; Sobel JD; Johnson PC; Tuazon CU; Kerkering T; Moskovitz BL; Powderly WG; Dismukes WE
    N Engl J Med; 1997 Jul; 337(1):15-21. PubMed ID: 9203426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.
    Kibbler CC
    Mycoses; 1999; 42 Suppl 2():121-4. PubMed ID: 10865918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
    Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
    Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation.
    Annaloro C; Oriana A; Tagliaferri E; Bertolli V; Della Volpe A; Soligo D; Ibatici A; Pozzoli E; Lambertenghi Deliliers GL
    Haematologica; 1995; 80(6):512-7. PubMed ID: 8647515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
    Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
    Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.